Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "THERAPEUTICS"


25 mentions found


Cramer’s Stop Trading: Viking Therapeutics
  + stars: | 2024-02-27 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer’s Stop Trading: Viking TherapeuticsCNBC’s Jim Cramer explains why he is keeping an eye on shares of Viking Therapeutics.
Persons: Jim Cramer Organizations: Therapeutics, Viking Therapeutics
Unity Software — Shares tumbled 15% after the video game developer forecasted that adjusted EBITDA would come in below analysts' expectations for the current quarter. Analysts polled by FactSet had expected $113 million in EBITDA, while Unity is expecting only between $45 million to $50 million. Workday's adjusted earnings came in at $1.57 a share, higher than the $1.47 expected by analysts polled by LSEG. AutoZone's earnings of $28.89 per share topped the $26.28 per share analysts had anticipated, according to LSEG. The company's $3.85 billion revenue was also higher than the anticipated $3.84 billion.
Persons: FactSet, LSEG, CarGurus, they'll, AutoZone, EBITDA, Wells, — CNBC's Michelle Fox, Tanaya Macheel, Sarah Min, Jesse Pound Organizations: Unity, LSEG, FactSet, PPG, Barclays, PPG Industries, FDA Locations: EBITDA, Cava, Wells Fargo, U.S, Canada
Norwegian Cruise Line — The cruise ship operator soared 18% on strong forward guidance. Unity expects adjusted EBITDA to range between $45 million and $50 million, versus the $113 million expected by analysts polled by FactSet. Viking Therapeutics — The clinical-stage biotech soared more than 90% after fulfilling primary and secondary endpoints in its Phase 2 GLP-1 study. Earnings came in at $1.57 per share, beating expectations of $1.47 per share, according to LSEG, formerly known as Refinitiv. Revenue of $1.92 billion matched analysts' expectations.
Persons: Viking, LSEG, Cava, Wells, Duolingo, CarGurus, — AutoZone, Microstrategy, , Sarah Min, Michelle Fox, Alex Harring, Jesse Pound, Yun Li Organizations: Cruise, Unity Software, FactSet, Therapeutics, Hess Corporation, Chevron, Exxon Mobil, China's, Offshore Oil Corp, Hess, Bank of America Securities, Seaport Research Partners, CleanSpark Locations: Cava
CNBC's Jim Cramer on Tuesday downplayed the competitive risk to Eli Lilly — a longtime holding in his Charitable Trust — presented by Viking Therapeutics ' new weight-loss drug data. Currently, Eli Lilly and Wegovy maker Novo Nordisk are the dominant players in the GLP-1 category. Eli Lilly and Novo Nordisk are far larger, worth around $733 billion and $550 billion as of Tuesday. Eli Lilly shares, among the best performers in the S & P 500 this year, fell slightly Tuesday. Cramer's Charitable Trust, the portfolio used by the CNBC Investing Club , has long owned Eli Lilly.
Persons: CNBC's Jim Cramer, Eli Lilly —, , Eli Lilly, Cramer, Eli Lilly's tirzepatide, David Ricks, Lilly's, retatrutide Organizations: Viking Therapeutics, Novo Nordisk, Viking, Leerink Partners, Charitable Trust, CNBC Locations: Lilly
Shares of Viking Therapeutics soared more than 80% in premarket trading Tuesday after the company's experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could grow into a $100 billion market by the end of the decade. Separately, the company said it expects to release early-stage trial data on an oral version of its weight loss drug. Viking Therapeutics' drug targets GLP-1 and another hormone called GIP. Those are the same hormones that Eli Lilly's weight loss and diabetes drugs, Zepbound and Mounjaro, target.
Persons: Brian Lian, Eli Lilly's Organizations: Viking Therapeutics, Viking, Food and Drug Administration
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. But Jim Cramer said the biggest theme in the market right now is cybersecurity. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .
Persons: Jim Cramer, Jim, Eli Lilly, Jim assuaged, it's, Wells Fargo, Jim Cramer's Organizations: CNBC, Palo Alto Networks, Viking Therapeutics
VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.
Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly
The Federal Trade Commission on Monday sued to block Kroger, the supermarket giant, from completing its $24.6 billion acquisition of the grocery chain Albertsons, saying the deal would hurt competition in the industry. The agency said the deal, which would be the largest supermarket merger in U.S. history, would also likely result in higher prices for groceries for consumers and, with fewer supermarkets, reduce the ability for grocery-store employees to negotiate higher wages and better working conditions. “This supermarket mega merger comes as American consumers have seen the cost of groceries rise steadily over the past few years,” Henry Liu, director of the F.T.C.’s Bureau of Competition, said in a news release. “Kroger’s acquisition of Albertsons would lead to additional grocery price hikes for everyday goods, further exacerbating the financial strain consumers across the country face today.”The agency’s lawsuit is the latest move by the Biden administration to take a tougher stance on mergers. In recent years it has challenged several big deals, including the drug maker Amgen’s $27.8 billion acquisition of the pharmaceutical company Horizon Therapeutics; JetBlue’s proposed $3.8 billion purchase of Spirit Airlines; and Microsoft’s $70 billion acquisition of the video game maker Activision Blizzard.
Persons: ” Henry Liu, Biden, JetBlue’s, Activision Blizzard Organizations: Federal Trade Commission, Kroger, Albertsons, Competition, Horizon Therapeutics, Spirit Airlines, Activision Locations:
Damian Williams, U.S. Attorney for the Southern District of New York, speaks during a press conference in New York City, Sept. 22, 2023. A personal pilot for British billionaire investor Joe Lewis pleaded guilty Monday to securities fraud related to the same insider trading scheme that Lewis admitted guilt in a month ago, federal prosecutors in New York said. The pilot, Patrick O'Connor, on multiple occasions, received material, nonpublic information about companies from Lewis that O'Connor then used to trade in shares of those firms, prosecutors said. Lewis is the principal owner of the Tavistock Group, a private investment firm, and controlled one or more board of director seats at companies in which he shared nonpublic information with O'Connor that the pilot then traded on, prosecutors said. Lewis, through a family trust, formerly controlled a majority ownership stake in the English Premier League soccer team Tottenham Hotspur.
Persons: Damian Williams, Joe Lewis, Lewis, Patrick O'Connor, O'Connor, Mirati Organizations: Attorney, Southern, of, Tavistock Group, English Premier League soccer, Tottenham Hotspur, Mirati Therapeutics, Manhattan U.S, Attorney's Locations: U.S, of New York, New York City, New York
Dividend stocks have come under pressure in today's higher interest rate environment as investors have turned to bonds with juicy yields. They all have a next-twelve-months price-to-earnings ratio lower than the index and a dividend yield higher than the index. It has a 4.3% dividend yield and has gained about 1% year to date. Another utility play, Exelon , has a 4% dividend yield and is also up less than 1% so far this year. Lastly, investment banking giant Morgan Stanley has slipped nearly 9% so far this year and has a 4% dividend yield.
Persons: Brian Belski, Belski, Hunter C, Gary, Exelon, Gilead, Morgan Stanley, Ted Pick, — CNBC's Michael Bloom Organizations: BMO Capital Markets, American Electric, American Electric Power, Icahn Capital, Gilead Sciences, Therapeutics Locations: U.S
Test tubes are seen in front of a displayed AbbVie logo in this illustration taken on May 21, 2021. AbbVie on Tuesday said longtime executive Robert Michael will become the company's new CEO, replacing Richard Gonzalez. Michael, who is AbbVie's president and chief operating officer, will become the company's second-ever CEO on July 1. Gonzalez, who has led the company since it spun out from Abbott Laboratories in 2013, will retire and become AbbVie's executive chairman. Now is the opportune time to hand the CEO role over to Rob," Gonzalez said in a release.
Persons: AbbVie, Robert Michael, Richard Gonzalez, Michael, Gonzalez, Rob Organizations: Abbott Laboratories, AbbVie, CNBC PRO Locations: Humira
There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."
Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema
A hotter-than-expected consumer price index on Tuesday sent stocks reeling, with the Dow posting its biggest drop in a year. Stocks bounced back over the next two days, helped by a softer retail sales report , only to slump again on Friday's hot producer price index for January. As we said this week, we're not overly concerned with the hotter-than-expected inflationary readings. Earnings season picks back up for the Club next week, with four holdings set to report quarterly results. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Wall, Stocks, we're, Palo, Fortinet, BCH's Bausch, Management doesn't, Dana, Bausch, Dr Pepper, Diana Shipping, Jim Cramer's, Jim Cramer, Jim, Jensen Huang, Walid Berrazeg Organizations: Dow Jones Industrial, Nasdaq, Dow, Federal Reserve, Club, Palo Alto, Palo, billings, Nvidia, Amazon, Microsoft, Bausch Health, Coterra Energy, Management, NYSE, Walmart, Axsome Therapeutics, Barclays Bank, Armstrong World Industries, Ceragon Networks, Tri Pointe Homes, Dana Incorporated, DigitalBridge, Oil States International, Systems, Allegion, CenterPoint Energy, Equitrans Midstream Corporation, Expeditors International of Washington, Alto Networks, SolarEdge Technologies, Enovix Corporation, Caesars Entertainment, Diamondback Energy, Toll, Ternium S.A, Celanese Corp, Chesapeake Energy, CVR Energy, Reserve, Vertiv Holdings Co, Properties Trust, Devices, HSBC Holdings plc, HSBC, Lomb, Sinclair Corporation, Pagaya Technologies, Gibraltar Industries, Garmin, NVIDIA, Rivian Automotive, Sunnova Energy International, Bros, Apache, Oil, Suncor Energy, Co, FNF, Sciences, Coeur D'Alene Mines, Trip.com, Joby Aviation, Resources, Alamos, Jackson, Nutrien, NTR, Pan, Sm Energy Company, Health, Newmont, Nikola Corporation, Cheniere Energy, Fiverr, Natural Resources, Point Credit, Lantheus Holdings, Builders, Grab Holdings, NICE, Dominion Energy, Harmony Biosciences Holdings, Teck Resources Limited, Intellia Therapeutics, Energy, Booking Holdings, Intuit, Semiconductor, Nation Entertainment, Vale S.A, Rocket Companies, Warner Bros ., AerCap Holdings, Natural Holdings, Calumet Specialty Products Partners, Frontier Communications, Jim Cramer's Charitable, CNBC, Lightrocket, Getty Locations: billings, Palo Alto, China, Xifaxan, Tri Pointe, Avista, Gibraltar, Coeur D'Alene, Pan American, Teck, Vale
Daniel Sundheim's D1 Capital made a handful of notable changes to its technology holdings in the fourth quarter, including closing out a position in a key artificial intelligence play. Sundheim also zeroed out his stake in software stock Salesforce , while trimming Microsoft and Facebook parent Meta by more than 60% and 20%, respectively. The role of large-cap tech stocks in driving up the market was so apparent that a group was dubbed the "Magnificent 7" for its outsized gains. Outside of big tech, Sundheim added to Mastercard and Philip Morris stakes. On the flip side, he dissolved stakes in a number of well-known stocks including Hilton , Las Vegas Sands , Liberty Media and Yum Brands .
Persons: Daniel Sundheim's, Sundheim, Philip Morris Organizations: Nvidia, Facebook, Meta, Viking Global, Mastercard, WWE, UFC, Lexeo Therapeutics, Hilton, Liberty Media, Yum Brands, Rivian, Electric Locations: Amazon, Vegas Sands
Bank of America also reiterated its neutral rating on Monday, while noting that leadership has "the playbook to turn things around." Diamondback Energy — The shale producer jumped 9.4% after announcing its purchase of Endeavor Energy, the biggest private company that produces natural resources from the Permian Basin. CymaBay Therapeutics , Gilead — Shares of CymaBay soared 25.4% after Gilead agreed to buy the drug developer. The deal comes as Gilead, whose shares were up around 1% in Monday's session, looks to expand beyond HIV drugs. Marqeta — The credit card technology stock added 5.7% after a Bank of America upgrade to buy from neutral.
Persons: Gilead, Bracken Darrell, Trimble, , Joe Ahlersmeyer, Piper Sandler, Teva, Samantha Subin, Sarah Min Organizations: New York Community Bancorp, Bank of America, Endeavor Energy, CymaBay Therapeutics, Gilead, VF Corp, Reuters, Mohawk Industries, Deutsche Bank, Citi, Space Development Agency, Teva Pharmaceutical —, JPMorgan, Nvidia Locations: Israel
“Xist is a very long RNA, 17,000 nucleotides long, or letters, and it associates with approximately almost 100 proteins,” Chang said. Chang wondered whether the clumps of protein molecules that arise when Xist connects with the X chromosome were a trigger for autoimmune disease. The experiments weren’t designed to show whether Xist or the related proteins cause autoimmune disease in the animals. The samples from patients with autoimmune disease produced higher levels of autoantibodies in reaction to proteins associated with Xist, the researchers found. Plus, environmental factors play a big role in autoimmune disease.
Persons: Howard Chang, Chang, , it’s, Montserrat Anguera, ” Anguera, wasn’t, ” Chang, “ It’s, Organizations: CNN, Stanford University, Cell, Stanford School of Medicine, University of Pennsylvania School of Veterinary Medicine Locations: United States, Montserrat
23andMe considers splitting up company to revive stock price
  + stars: | 2024-02-08 | by ( Ashley Capoot | In | ) www.cnbc.com   time to read: +3 min
Shares of 23andMe sank 21% on Thursday, a day after the genetic testing company reported dismal fiscal third-quarter results and discussed splitting itself in two to help juice its stock price. 23andMe reported revenue of $45 million for the quarter, down from the $67 million it reported in the same period last year. The five-time CNBC Disruptor 50 company went public in 2021 via a merger with a special purpose acquisition company, a deal that valued the company at around $3.5 billion. The company has launched additional therapeutics and research businesses, but its share price has tumbled more than 95% from its peak. They lowered their target price for the stock to 85 cents from 90 cents.
Persons: 23andMe, Anne Wojcicki, Sergey Brin, Forbes, Joe Selsavage, Selsavage Organizations: TechCrunch, 23andMe, Nasdaq, U.S . Securities, Exchange Commission, CNBC Disruptor, Citi, CNBC PRO Locations: San Francisco , California, 23andMe
Cramer’s Stop Trading: Akero Therapeutics
  + stars: | 2024-02-06 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer’s Stop Trading: Akero TherapeuticsCNBC’s Jim Cramer explains why he is keeping an eye on shares of Akero Therapeutics.
Persons: Jim Cramer Organizations: Akero Therapeutics
The Russell 1000 , which tracks the top 1,000 largest companies — large- and mid-cap names — is up about 3% in 2024. With this in mind, CNBC Pro screened for the stocks making a comeback in 2024. However, the consensus price target is just 4.6% from its current levels — putting into question whether there's more room for upside. Just 35.7% of analysts are bullish on the shares, and the average price target implies shares can grow just 4.3%. Sarepta Therapeutics has soared 27.4% this year — and it could jump 20.1% more according to its consensus price target, per LSEG.
Persons: Russell, they're, Merck's, Sarepta Organizations: CNBC Pro, Pharmaceutical, Merck, Verizon, Barclays, VZ, LSEG, Novo Nordisk, Sarepta Therapeutics Locations: Novo
'Mad Money' host Jim Cramer takes a closer look at Axsome Therapeutics. Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email
Persons: Jim Cramer Organizations: Axsome Therapeutics
Merck on Thursday reported fourth-quarter revenue and adjusted earnings that topped estimates as it saw strong demand for its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. Excluding acquisition and restructuring costs, Merck earned 3 cents per share for the fourth quarter. Merck raked in $14.63 billion in revenue for the quarter, up 6% from the same period a year ago. Analysts surveyed by LSEG expected Merck to forecast full-year sales of $63.52 billion and adjusted earnings of $8.42 per share. Merck recorded charges of $190 million related to the program in the fourth quarter, which is excluded from its adjusted results.
Persons: Merck Organizations: Merck & Co, New York Stock Exchange, Merck, LSEG, Harpoon Therapeutics Locations: New York City , New York, U.S
Here are Thursday's biggest calls on Wall Street: Morgan Stanley downgrades ZoomInfo to equal weight from overweight Morgan Stanley said it sees a slowing recovery for the software company. Morgan Stanley reiterates General Motors as overweight Morgan Stanley said it's standing by the auto giant and that GM shares are "cheap." Mizuho reiterates Nvidia as buy Mizuho said it's standing by the stock heading into its GTC Conference in March. Morgan Stanley names Docebo a top pick Morgan Stanley named the ed-tech company a top pick. " Morgan Stanley reiterates Bloom Energy as overweight Morgan Stanley said the energy company is an "underappreciated AI winner."
Persons: Morgan Stanley downgrades ZoomInfo, Morgan Stanley, Oppenheimer, AAPL, it's, Mizuho, Goldman Sachs, Goldman, Redburn, Tesla, Daiwa, Jefferies, StoneCo, Wells, JPMorgan downgrades Lennox, LII, Docebo, Kraft Heinz, Mondelez, Kate McShane, Wolfe, Cash Organizations: OW, Apple, Motors, Nvidia, Conference, Citi, Qualcomm, Samsung, Deutsche Bank, Deutsche, Humana, Microsoft, Rockwell Automation, Rockwell, JPMorgan, UBS, SilverBow Resources, Regency, Kraft, Target, RBC downgrades New York Community Bancorp, RBC, New, Community Bancorp, Bloom Energy, Boston Scientific, Mizuho Locations: Boston
Acute pain is usually caused by injury, surgery, illness, trauma or painful medical procedures and is likely to ease with time. Around 80 million patients are prescribed a medicine for their moderate-to-severe acute pain every year in the U.S., Vertex said in a release. Last year, the company's painkiller produced positive results in a mid-stage trial in diabetes patients suffering from a chronic nerve condition. Those two procedures are commonly used in studies of people with acute pain. Jefferies analyst Michael Yee said the drug's failure to meet that goal is in line with expectations and that overall, the late-stage trial results released Tuesday are positive.
Persons: Reshma Kewalramani, painkiller, Michael Yee Organizations: Vertex Pharmaceuticals, Food and Drug, Wall Street, CRISPR Therapeutics, Jefferies Locations: Boston, U.S
Cramer's Lightning Round: 'Hard pass' on Surgery Partners
  + stars: | 2024-01-30 | by ( Julie Coleman | ) www.cnbc.com   time to read: +1 min
Stock Chart Icon Stock chart icon Surgery Partners's year-to-date stock performance. Stock Chart Icon Stock chart icon Energy Transfer's year-to-date stock performance. Stock Chart Icon Stock chart icon DigitalOcean's year-to-date stock performance. Stock Chart Icon Stock chart icon Vodafone's year-to-date stock performance. Stock Chart Icon Stock chart icon MP Materials' year-to-date stock performance.
Persons: it's, they're, I'm Organizations: Surgery Partners, Energy, Vodafone, Verizon, Therapeutics, CRISPR Therapeutics
American Airlines — The airline stock added 1.5% following an upgrade to buy from neutral at Citi. "North America's network carriers' diversified revenue streams and solid demand for premium cabin offerings appear to provide them with superior positioning in this post-pandemic environment," wrote analyst Stephen Trent. Builders FirstSource — The building materials manufacturer edged 2% higher following an upgrade to buy from neutral at Bank of America. ZoomInfo Technologies — The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. "We believe it is a classic self-help story that is set to outperform," the analyst wrote, underscoring the company's revenue growth reacceleration and new AI products as potential catalysts.
Persons: Stephen Trent, Flywire, Morgan Stanley, Omar Nokta, Hershey, Wells, Steven Cahall, , Cowen, Rafe Jadrosich, Julien Dumoulin, Smith, FactSet, Koji Ikeda, McGrath RentCorp — McGrath RentCorp, CNBC's Michelle Fox, Alexander Harring, Sarah Min, Jesse Pound Organizations: JPMorgan, American Airlines —, Citi, Zim Integrated Shipping Services —, Jefferies, Warner Bros, Bank of America, Bloom Energy, Koninklijke Philips —, Food and Drug Administration, Technologies, WillScot Mobile Locations: Albemarle, Netherlands
Total: 25